CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference
CG Oncology (NASDAQ: CGON), a late-stage clinical biopharmaceutical company specializing in bladder cancer therapeutics, has announced its upcoming participation at the TD Cowen 45th Annual Health Care Conference. Arthur Kuan, Chairman & Chief Executive Officer, will deliver a presentation in Boston, MA on March 5, 2025, at 11:10 am ET.
The presentation will be accessible via live audio webcast through the Investor Relations section of www.cgoncology.com. Following the live event, a replay will remain available for approximately 90 days on the company's website.
CG Oncology (NASDAQ: CGON), un'azienda biofarmaceutica clinica in fase avanzata specializzata nelle terapie per il cancro alla vescica, ha annunciato la sua prossima partecipazione alla 45ª Conferenza Annuale sulla Salute di TD Cowen. Arthur Kuan, Presidente e Amministratore Delegato, presenterà a Boston, MA il 5 marzo 2025, alle 11:10 ET.
La presentazione sarà accessibile tramite audio webcast dal vivo nella sezione Relazioni con gli Investitori di www.cgoncology.com. Dopo l'evento dal vivo, una registrazione rimarrà disponibile per circa 90 giorni sul sito web dell'azienda.
CG Oncology (NASDAQ: CGON), una empresa biofarmacéutica clínica en etapa avanzada especializada en terapias para el cáncer de vejiga, ha anunciado su próxima participación en la 45ª Conferencia Anual de Salud de TD Cowen. Arthur Kuan, Presidente y Director Ejecutivo, realizará una presentación en Boston, MA el 5 de marzo de 2025, a las 11:10 am ET.
La presentación será accesible a través de una transmisión de audio en vivo en la sección de Relaciones con Inversores de www.cgoncology.com. Después del evento en vivo, una repetición estará disponible durante aproximadamente 90 días en el sitio web de la empresa.
CG Oncology (NASDAQ: CGON), 방광암 치료제를 전문으로 하는 후기 단계 임상 바이오제약 회사가 TD Cowen 제45회 연례 건강 관리 컨퍼런스에 참여할 예정이라고 발표했습니다. Arthur Kuan, 회장 겸 CEO가 2025년 3월 5일 오전 11시 10분 ET에 매사추세츠주 보스턴에서 발표를 진행할 예정입니다.
발표는 www.cgoncology.com의 투자자 관계 섹션을 통해 실시간 오디오 웹캐스트로 접근할 수 있습니다. 실시간 이벤트 후, 재생은 회사 웹사이트에서 약 90일 동안 제공될 것입니다.
CG Oncology (NASDAQ: CGON), une entreprise biopharmaceutique clinique en phase avancée spécialisée dans les thérapies contre le cancer de la vessie, a annoncé sa prochaine participation à la 45ème Conférence Annuelle sur la Santé de TD Cowen. Arthur Kuan, Président et Directeur Général, fera une présentation à Boston, MA le 5 mars 2025 à 11h10 ET.
La présentation sera accessible via un webcast audio en direct dans la section Relations Investisseurs de www.cgoncology.com. Après l'événement en direct, un replay sera disponible pendant environ 90 jours sur le site web de l'entreprise.
CG Oncology (NASDAQ: CGON), ein biopharmazeutisches Unternehmen in der späten klinischen Phase, das sich auf Therapeutika gegen Blasen Krebs spezialisiert hat, hat seine bevorstehende Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen angekündigt. Arthur Kuan, Vorsitzender und CEO, wird am 5. März 2025 um 11:10 Uhr ET in Boston, MA eine Präsentation halten.
Die Präsentation wird über einen Live-Audio-Webcast im Bereich Investor Relations von www.cgoncology.com zugänglich sein. Nach der Live-Veranstaltung wird eine Wiederholung für etwa 90 Tage auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
IRVINE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, is scheduled to present at the TD Cowen 45th Annual Health Care Conference in Boston, MA on Wednesday, March 5, 2025, at 11:10 am ET.
Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.cgoncology.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90 days.
About CG Oncology
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from its innovative immunotherapies to live with dignity and have an enhanced quality of life.
Contacts
Media
Sarah Connors
VP, Communications and Patient Advocacy
(508) 654-2277
sarah.connors@cgoncology.com
Investor Relations
Chau Cheng
VP, Investor Relations
(949) 342-8939
chau.cheng@cgoncology.com
FAQ
When is CG Oncology (CGON) presenting at the TD Cowen Healthcare Conference 2025?
How can investors access CG Oncology's (CGON) TD Cowen conference presentation?
How long will CGON's TD Cowen conference presentation replay be available?
What is CG Oncology's (CGON) main therapeutic focus?
